BetterLife Pharma (XCNQ:BETR) Interest Expense : C$-0.32 Mil (TTM As of Jul. 2024)

View and export this data going back to 2017. Start your Free Trial

What is BetterLife Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BetterLife Pharma's interest expense for the three months ended in Jul. 2024 was C$ -0.21 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jul. 2024 was C$-0.32 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BetterLife Pharma's Operating Income for the three months ended in Jul. 2024 was C$ -1.11 Mil. BetterLife Pharma's Interest Expense for the three months ended in Jul. 2024 was C$ -0.21 Mil. BetterLife Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BetterLife Pharma Interest Expense Historical Data

The historical data trend for BetterLife Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma Interest Expense Chart

BetterLife Pharma Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Interest Expense

Get a 7-Day Free Trial

-0.43

-0.04

-0.06

-0.07

-0.05

BetterLife Pharma Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.01	-0.04	-0.06	-0.21

BetterLife Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.32 Mil.

BetterLife Pharma (XCNQ:BETR) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BetterLife Pharma's Interest Expense for the three months ended in Jul. 2024 was C$-0.21 Mil. Its Operating Income for the three months ended in Jul. 2024 was C$-1.11 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jul. 2024 was C$1.37 Mil.

BetterLife Pharma's Interest Coverage for the quarter that ended in Jul. 2024 is calculated as

BetterLife Pharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

BetterLife Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (XCNQ:BETR) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

BETRF:USA NPAU:Germany

Address

1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6

Website

https://www.abetterlifepharma.com

BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.

Executives